VRAX Stock Risk & Deep Value Analysis
Virax Biolabs Group Ltd
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About VRAX Stock
We analyzed Virax Biolabs Group Ltd using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran VRAX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
VRAX Risk Analysis & Red Flags
What Could Go Wrong
The company's historical inability to generate significant revenue and persistent cash burn mean the recently raised $5M will likely be quickly exhausted. Without substantial product commercialization success or another capital raise (which implies further significant dilution), the company faces severe liquidity issues and potential delisting, likely leading to a near-total loss for investors.
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
High
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Persistent negative free cash flow (based on historical financials and absence of recent positive reports)
- ⚠
History of significant share dilution (warrant exercise, approved equity plan, potential future raises)
- ⚠
Very low share price ($0.20) and approved reverse stock split (often a sign of financial distress/delisting risk)
- ⚠
Lack of detailed financial reporting (10-K/10-Q) in available search results, indicating limited transparency or struggling operations.
Upcoming Risk Events
- 📅
Continued high cash burn rate without corresponding revenue growth
- 📅
Failure to raise additional capital, leading to severe liquidity crisis
- 📅
Inability to commercialize diagnostic products or secure necessary regulatory approvals
- 📅
Increased competition from larger, more established diagnostic companies
When to Reconsider
- 🚪
Exit if quarterly cash burn significantly increases without a clear path to profitability
- 🚪
Sell if price drops below $0.10 for a sustained period or fails to respond positively to reverse split
- 🚪
Announcement of further major share dilution without clear, immediate funding for substantial growth initiatives.
Unlock VRAX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Virax Biolabs Group Ltd (VRAX) Do?
Market Cap
$772,779.3
Sector
Healthcare
Industry
Biotechnology
Employees
19
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary diagnostics under the ViraxVet brand. It also provides ViraxImmune, a T cell In vitro diagnostic device and wellness mobile application; and service, such as antibody engineering, custom peptides, protein sequencing, vaccine efficacy testing, immunology lab services, kits and reagents. In addition, the company is involved in research and development activities; and provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, corporations, independent laboratories, large hospital systems and public and private institutions, as well as distributor customers. The company operates in the United Kingdom, the United States, and China. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.
Visit Virax Biolabs Group Ltd WebsiteInvestment Thesis
Virax Biolabs presents an extremely high-risk, high-reward bet on the successful development and commercialization of diagnostic technologies for post-acute infection syndromes like Long COVID. The recent capital injection and ISO certifications provide a thin lifeline and some operational credibility, making it a speculative play on a potential turnaround in a large addressable market. A 10x return would require near-perfect execution and significant market penetration.
Is VRAX Stock Undervalued?
Unlock the full AI analysis for VRAX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
VRAX Price Targets & Strategy
12-Month Target
$0.40
Bull Case
$2.00
Bear Case
$0.05
Valuation Basis
Highly speculative; target reflects potential for continued retail momentum and successful commercialization of a key diagnostic product, but lacks fundamental valuation support. 10x target of $2.00 is purely aspirational based on significant market penetration of PAIS diagnostics.
Entry Strategy
Extremely speculative. Only for high-risk tolerant investors. Consider a very small, speculative position size (e.g., <0.5% of total portfolio) on dips towards $0.10-$0.15 if any further positive operational news emerges or after reverse split implementation.
Exit Strategy
Take partial profits if price approaches $0.40-$0.50 (double from current levels). Stop loss below $0.10 to protect capital from further declines or potential delisting.
Portfolio Allocation
0.5% for aggressive, high-risk capital only.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is VRAX Financially Healthy?
Profitability
Gross Margin
-1515.05%
Operating Margin
-196303.34%
Net Margin
-188748.83%
Return on Equity
-102.54%
Revenue Growth
-96.48%
EPS
$-1.25
Balance Sheet
Current Ratio
7.27
Quick Ratio
6.33
Debt/Equity
0.07
Other
Beta (Volatility)
1.45
Does VRAX Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Not applicable
Currently, Virax Biolabs has no discernible economic moat. Its ability to compete relies on successful product development, regulatory approval, and effective commercialization of proprietary diagnostic technology, none of which are yet proven to be unique or defensible over the long term.
Moat Erosion Risks
- •Intense competition from larger, better-funded diagnostic companies
- •Rapid technological advancements by rivals rendering their technology obsolete
- •Challenges in securing or defending intellectual property rights for new diagnostics
VRAX Competitive Moat Analysis
Sign up to see competitive advantages
VRAX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bullish (driven by recent pre-market price surge and speculative retail interest; however, highly volatile and susceptible to shifts)
Institutional Sentiment
Neutral/Negative (absence of analyst coverage and institutional ownership suggests avoidance due to high risk profile and limited fundamentals)
Insider Activity (Form 4)
No Form 4 filings or insider trading activity is disclosed in the search results provided. The warrant exercise was a private placement capital raise, not a typical insider transaction.
Options Flow
Normal options activity (given the small market capitalization and low share price, significant institutional options flow is unlikely)
Earnings Intelligence
Next Earnings
Estimated late May / early June 2026 (for Q1 2026, based on typical FPI reporting schedules)
Surprise Probability
Medium (given the lack of analyst coverage, any reported revenue or specific operational progress could be a surprise, but deep losses are also expected)
Historical Earnings Pattern
Irregular/Unknown (due to infrequent recent comprehensive financial reporting and company's early stage of development).
Key Metrics to Watch
Competitive Position
Top Competitor
No specific best-in-class competitor can be identified from the provided research, as VRAX operates in a highly fragmented and competitive diagnostics market. Larger, established diagnostic companies (e.g., Quest Diagnostics, LabCorp) or specialized biotech firms developing similar products would be indirect competitors.
Market Share Trend
Not applicable; VRAX currently has minimal to zero discernible market share.
Valuation vs Peers
N/A - The company is too early-stage, with minimal to no revenue and persistent losses, making traditional valuation comparisons (P/E, EV/Sales) against profitable peers largely irrelevant or misleading.
Competitive Advantages
- •ISO 13485:2016 and ISO 9001:2015 certifications (demonstrates commitment to quality for medical device development)
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive VRAX Stock Higher?
Near-Term (0-6 months)
- •Implementation of approved reverse stock split (expected 2026 Q2)
- •Q1 2026 Earnings Report (estimated late May / early June 2026)
- •Further announcements regarding PAIS diagnostic product development or regulatory progress
Medium-Term (6-18 months)
- •Successful product launch and initial revenue generation from PAIS diagnostics (6-18 months)
- •Establishment of key distribution partnerships in relevant markets
- •Additional, non-dilutive capital raises or strategic investments
Long-Term (18+ months)
- •Becoming a recognized and competitive player in the niche PAIS diagnostics market (18+ months)
- •Significant market share gains in specific diagnostic segments
- •Expansion into new related diagnostic or personalized medicine areas
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for VRAX?
- ✓
Consistent and increasing revenue generation from new product sales
- ✓
Significant reduction in quarterly cash burn rate or achievement of cash flow positivity
- ✓
Major strategic partnerships for product distribution or co-development
Bull Case Analysis
See what could go right with Premium
Competing with VRAX
See how Virax Biolabs Group Ltd compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Virax Biolabs Group Ltd VRAX | $772,779.3 | 1.5 | — | — | -188748.8% | -96.5% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Virax Biolabs Group Ltd Makes Money
Virax Biolabs Group Ltd is a diagnostics and personalized medicine company that aims to develop, commercialize, and distribute innovative technologies, primarily focused on infectious diseases and post-acute infection syndromes (PAIS), such as Long COVID. They currently generate little to no revenue and rely on capital raises to fund their research and development efforts with the goal of bringing new diagnostic products to market and generating sales.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Virax Biolabs Group Ltd (VRAX)?
As of April 13, 2026, Virax Biolabs Group Ltd has a DVR Score of 1.5 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Virax Biolabs Group Ltd?
Virax Biolabs Group Ltd's market capitalization is approximately $772,779.3. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Virax Biolabs Group Ltd use?
VRAX is the ticker symbol for Virax Biolabs Group Ltd. The company trades on the NCM.
What is the risk level for VRAX stock?
Our analysis rates Virax Biolabs Group Ltd's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Virax Biolabs Group Ltd's revenue growing?
Virax Biolabs Group Ltd has reported revenue growth of -96.5%. Revenue has been declining, which warrants closer examination.
Is VRAX stock profitable?
Virax Biolabs Group Ltd has a profit margin of -188748.8%. The company is currently unprofitable.
How often is the VRAX DVR analysis updated?
Our AI-powered analysis of Virax Biolabs Group Ltd is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 13, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for VRAX (Virax Biolabs Group Ltd) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.